Remantadin-КR (rimantadine) tablets 50 mg. №20

Description

Remantadin-КR (rimantadine) tablets 50 mg. №20

Composition

active ingredient: rimantadine hydrochloride;

1 tablet contains rimantadine hydrochloride – 0.05 g;

excipients: lactose monohydrate, potato starch, microcrystalline cellulose, magnesium stearate, anhydrous colloidal silicon dioxide.

Dosage form

Tablets.

Basic physical and chemical properties: tablets of white or white color with a yellowish tint.

Pharmacological group

Antivirals of direct action.
ATX code J05A С02.

Pharmacological properties

Rimantadine hydrochloride – a derivative of amantadine, exhibits pronounced antiviral activity. It is effective against various influenza A viruses, and also exhibits an antitoxic effect in influenza caused by type B virus. Rimantadine inhibits viral replication in the early stages of the cycle by disrupting the formation of the viral envelope. Genetic studies have shown that the specific protein of the M2 gene of the virion is important in the antiviral effect of rimantadine against the influenza A virus. In vitro, rimantadine inhibits the replication of all three antigenic subtypes (H1N1, H2N2, H3N3) of the influenza virus identified in humans. Rimantadine does not affect the immunogenic properties of the inactivated influenza A vaccine.

Rimantadine is also effective against arboviruses, which are the causative agents of tick-borne encephalitis.

Indications

Remantadin-КR shown:

• for the prevention and treatment of influenza;
• for the prevention of viral tick-borne encephalitis in adults.

Contraindications

The drug Remantadin-КR is not used:

• with hypersensitivity to rimantadine, other components;
• with acute liver diseases;
• with diabetes mellitus;
• with acute and chronic kidney disease;
• with thyrotoxicosis;
• during pregnancy, breastfeeding;
• children under the age of 7.

Used with caution:

• with arterial hypertension;
• with atherosclerosis of the vessels of the brain;
• with epilepsy;
• with diseases of the gastrointestinal tract.

Application during pregnancy and lactation

The use of the drug Remantadin-КR during pregnancy and breastfeeding is contraindicated.

Method of administration and dosage

Remantadin-КR is administered orally (after meals).

Treatment should be started within 24 to 48 hours after the onset of symptoms.

• The standard adult dose for the treatment of influenza is 100 mg 3 times a day on the 1st day; 100 mg 2 times a day on days 2–3, 100 mg 1 time a day on days 4–5.
• The standard dose for adults for the prevention of influenza is 50 mg once a day, the course is up to 30 days. Children over 7 years old – 50 mg once a day, the course – up to 15 days.

Overdose

Symptoms: increased urination, increased lacrimation, fever, agitation, chills, constipation, dysphagia, increased sweating, stomatitis, eye pain, hypesthesia.

Treatment in case of overdose: gastric lavage, intake of enterosorbents, symptomatic therapy, if necessary, hemodialysis.

Side effects:

• Cardiovascular disorders: palpitations, arterial hypertension, cerebrovascular disorders, edema, heart failure, cardiac conduction disorders, tachycardia, increased risk of hemorrhagic stroke, fainting.
• Neurological disorders: headache, tremors, dizziness, ataxia (discoordination of movements), seizures, hyperkinesis (spontaneous movements), insomnia, drowsiness, excessive fatigue, impaired concentration, increased excitability, confusion, nervousness, depression, anxiety, hallucinations, euphoria …
• Otolaryngological disorders: parosmia, change or loss of taste, tinnitus.
• Respiratory disorders: shortness of breath, cough, bronchospasm.
• Dermatological disorders: skin rash, pallor of the skin, itching, urticaria.
• Digestive disorders: dyspepsia, dry mouth, nausea, abdominal pain, diarrhea, vomiting, anorexia.
• Others: exacerbation of chronic diseases, galactorrhea.